Co-Authors
This is a "connection" page, showing publications co-authored by Michael Fralick and Aaron Kesselheim.
Connection Strength
5.485
-
Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety. J Gen Intern Med. 2018 06; 33(6):792-794.
Score: 0.770
-
The Price of Crossing the Border for Medications. N Engl J Med. 2017 10 26; 377(17):1699-1700.
Score: 0.739
-
Low-Dose Desmopressin Nasal Spray and FDA Approval-Reply. JAMA. 2017 09 19; 318(11):1071-1072.
Score: 0.734
-
The Price of Crossing the Border for Medications. N Engl J Med. 2017 Jul 27; 377(4):311-313.
Score: 0.726
-
FDA Approval of Desmopressin for Nocturia. JAMA. 2017 05 23; 317(20):2059-2060.
Score: 0.718
-
Three design aspects for high quality post-marketing cohort studies. BMJ. 2017 04 12; 357:j1851.
Score: 0.712
-
Periodic benefit-risk evaluation reports have substantial promise to guide patient care and should be made publicly available. Pharmacoepidemiol Drug Saf. 2017 05; 26(5):597-599.
Score: 0.704
-
The Shortage of Normal Saline in the Wake of Hurricane Maria. JAMA Intern Med. 2018 07 01; 178(7):885-886.
Score: 0.194
-
Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2018 01 01; 178(1):55-63.
Score: 0.187